S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NYSE:CRY

CryoLife (CRY) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free CRY Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$17.19
▼
$21.72
52-Week Range
N/A
Volume
7,792 shs
Average Volume
198,221 shs
Market Capitalization
$703.22 million
P/E Ratio
596.20
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
CRY stock logo

About CryoLife Stock (NYSE:CRY)

CryoLife, Inc. engages in the manufacture, process and distribution of medical devices and implantable human tissues. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes revenues from sales of BioGlue products, aortic stents and stent grafts, On-X products, CardioGenesis cardiac laser therapy, PerClot, and PhotoFix. The Preservation Services segment focuses on revenues from preservation of cardiac and vascular implantable human tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

CRY Stock News Headlines

April 8, 2024 | uk.finance.yahoo.com
Global Surgical Sealants and Adhesives Market Analysis Report 2024-2030: A USD 5.39 Billion Market by 2030, with 11.8% Forecasted CAGR
March 9, 2024 | investing.com
Braskem SA Class A (BAK)
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
February 16, 2024 | markets.businessinsider.com
Artivion Secures Buy Rating: Strong Financials and Growth Trajectory Propel Price Target Increase
February 14, 2024 | markets.businessinsider.com
CryoLife earnings: here's what to expect
February 6, 2024 | finance.yahoo.com
Hemostats Market revenue to exceed USD 5000 Million by 2033, says Research Nester
January 31, 2024 | markets.businessinsider.com
Buy Rating on Artivion’s Stock Backed by Strong PERSEVERE Study Results and Market Potential
January 15, 2024 | finance.yahoo.com
Global Cord Blood & Tissue Banking Industry Report Market Size, Segmentation, & Forecasts, 2024
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
January 10, 2024 | finance.yahoo.com
Q3 2024 Park Aerospace Corp Earnings Call
December 28, 2023 | seekingalpha.com
Artivion Stock: A First Assessment
December 19, 2023 | finance.yahoo.com
Pediatric Heart Valve Repair and Replacement Market to Witness 2.7% CAGR, Reaching US$ 4,490.5 Million by 2034 | Future Market Insights, Inc.
November 21, 2023 | markets.businessinsider.com
Why Symbotic Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
November 1, 2023 | benzinga.com
Bone Cement Market Size, Growth & Statistical Report from 2023 to 2030
October 19, 2023 | finance.yahoo.com
Aortic Stent Grafts Market to Surpass 3.01 Billion by 2030 Drives Due to Medical Advancements
October 3, 2023 | finance.yahoo.com
Global Aortic Stents Grafts Market to Record a CAGR of 5% and Reach US$ 4.2 billion by 2033 | Future Market Insights, Inc.
September 14, 2023 | benzinga.com
Heart Valve Devices Market to be Worth US$ 37.5 Billion by 2033 | Fact.MR Report
August 25, 2023 | finance.yahoo.com
Cardiac Sutures Global Market Report 2023
August 5, 2023 | msn.com
Needham Reiterates Artivion (AORT) Buy Recommendation
July 4, 2023 | finance.yahoo.com
Biosurgery Global Market Report 2023
June 9, 2023 | finance.yahoo.com
Dermatology Lasers Global Market Report 2023
May 21, 2023 | uk.finance.yahoo.com
CryoLife, Inc. (CYL.F)
May 17, 2023 | finance.yahoo.com
Laser Therapy Global Market Report 2023: Increasing Demand from Non-invasive Laser Surgeries Drives Growth
May 17, 2023 | marketwatch.com
Regenerative Medicine Market (2023-2030): Research Report, Growth, Trends and Competitive Analysis
May 17, 2023 | marketwatch.com
Global Tissue Level Implant Market to Witness Significant Growth Due to Increasing Adoption Forecast 2023-2030
May 17, 2023 | marketwatch.com
Global Hemostatic Gel Market [2023-2030] | Growing at a CAGR 5.2% (Expected to Reach 1356.5)
May 16, 2023 | marketwatch.com
Global Organ and Tissue Transplantation and Alternative Market Size 2023-2031 Business Strategies by Absolute Reports | with [94 Pages]
See More Headlines
Receive CRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CryoLife and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
Health Care Equipment
Current Symbol
NYSE:CRY
CUSIP
22890310
CIK
784199
Web
www.cryolife.com
Phone
(770) 419-3355
Fax
770-426-0031
Employees
1,200
Year Founded
1984

Profitability

EPS (Most Recent Fiscal Year)
$0.03
Trailing P/E Ratio
596.20
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-16,680,000.00
Net Margins
0.63%
Pretax Margin
0.41%
Return on Equity
4.24%
Return on Assets
1.63%

Debt

Debt-to-Equity Ratio
0.99
Current Ratio
4.21
Quick Ratio
2.93

Sales & Book Value

Annual Sales
$253.23 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
23.30
Book Value
$8.46 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
39,330,000
Free Float
37,560,000
Market Cap
$703.22 million
Optionable
Optionable
Beta
1.53

Social Links

12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • James Patrick Mackin
    Chairman, President & Chief Executive Officer
  • David Ashley Lee
    Chief Operating & Financial Officer, Executive VP
  • Scott B. Capps
    Vice President-Clinical Research
  • Franz Peter Barthold
    Vice President-Research & Development
  • Marshall S. Stanton
    Chief Medical Officer & SVP-Clinical Research

Key Competitors

View All Competitors

CRY Stock Analysis - Frequently Asked Questions

How were CryoLife's earnings last quarter?

CryoLife, Inc. (NYSE:CRY) issued its quarterly earnings data on Thursday, November, 4th. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.04 by $0.22. The medical equipment provider had revenue of $72.21 million for the quarter, compared to analysts' expectations of $72.90 million. CryoLife had a trailing twelve-month return on equity of 4.24% and a net margin of 0.63%. During the same quarter in the prior year, the firm posted $0.13 EPS.

What is J. Patrick Mackin's approval rating as CryoLife's CEO?

53 employees have rated CryoLife Chief Executive Officer J. Patrick Mackin on Glassdoor.com. J. Patrick Mackin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of CryoLife own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CryoLife investors own include Energy Transfer (ET), AT&T (T), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Enterprise Products Partners (EPD), Gilead Sciences (GILD), Netflix (NFLX), Zoetis (ZTS), Ares Capital (ARCC) and Edwards Lifesciences (EW).

Does CryoLife have any subsidiaries?
The following companies are subsidiares of CryoLife: AuraZyme Pharmaceuticals Inc., Cardiogenesis Corporation, CryoLife Asia Pacific PTE. Ltd., CryoLife Canada Inc., CryoLife Europa Ltd., CryoLife France SAS., CryoLife Germany HoldCo GmbH, CryoLife Germany TopCo GmbH, CryoLife International Inc., Hemosphere, JOTEC AG, JOTEC Cardiovascular S.L., JOTEC Polska Sp. z.o.o, JOTEC Sales GmbH, JOTEC UK Ltd., JOTEC do Brasil, JOTEC s.r.l., Jolly Buyer Acquisition GmbH, Jotec, On-X Life Technologies Holdings Inc., On-X Life Technologies Inc., and Valve Special Purpose Co. LLC.
Read More
This page (NYSE:CRY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
SHOCKING Crypto Leak…
Crypto 101 Media
Man Who Predicted 2008: “This Will be Worse.”
Altimetry
Fed launches fourth dollar overhaul
Stansberry Research